FDA Approves LEUPROLIDE ACETATE — Amneal Pharmaceuticals LLC

# FDA Approves Generic Leuprolide Acetate for Amneal Pharmaceuticals Amneal Pharmaceuticals LLC received FDA approval for its generic leuprolide acetate subcutaneous injection, expanding the competitive landscape in the hormone therapy market and potentially lowering costs for patients treating prostate cancer, endometriosis, and other hormone-sensitive conditions. The approval of this subcutaneous formulation is expected to increase price competition against branded alternatives and capture significant market share in the estimated multi-billion-dollar leuprolide market.